Issue 2: Pharma Digest

Issue 2: Pharma Digest

Welcome to your bi-weekly newsletter.

The industry has never been more primed to drive positive change, however post-Covid health systems are at their limit, so pharma must again evolve to take the lead. Keeping your organisation up to speed can be tricky - we're here to help solve that problem.

The Digest is for you, the valued members of our Pharma community. Receive the latest market movements, breaking pharma news, business-critical whitepapers and content, and updates on our exclusive executive summits. Don’t forget to subscribe using the button above.

Let's get started.


Industry Trends Report

No alt text provided for this image

Leaders from across the industry have shared their predictions for pharma's top challenges. With expert insights from senior leaders across the value chain, this report sheds light on how pharma and healthcare leadership will come together and build frameworks for the future of our industry.??See what's to come for Pharma in 2023 with this exclusive new Reuters Events report here:?https://bit.ly/3IIs2v8


Data driven decisions for medical affairs leaders

Calling all medical affairs leaders! Reuters Events Pharma are running a global industry survey on data driven decisions for medical affairs. How are you capturing, analyzing and communicating insights to help your organization take action? We’d love to have your input – it’s anonymous and you will also receive the report with the findings and expert analysis.

Please share your thoughts here.

No alt text provided for this image

This Week's Top 5 Pharma News to Watch

1. Pfizer, GSK face FDA panel review in race for RSV vaccines (Reuters.com, February 28)

2. Moderna pays US government $400M 'catch-up payment' under new COVID-19 vaccine license (FiercePharma, February 24)

3. Merck scraps third prostate cancer study as Keytruda therapy disappoints (Reuters.com, February 28)

4. Sanofi sings a song for rare disease and equitable care (Pharmaphorum, February 28)

5. Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude ?(BiopharmaDive, February 21)


No alt text provided for this image

Reuters Events Pharma USA is taking place in less than 4 weeks. Join 1000+ of North America’s visionary pharma changemakers, leading solution providers, patient experts and industry heavyweights to catapult commercial excellence, ingrain patient-first strategies into the heart of pharma’s fabric and heed the long-awaited rebirth of America’s healthcare system.?#REpharmaUSA?

Register by 03/10 and automatically enter our prize draw to win a complimentary pass for a colleague (worth $2,499) and tackle team hurdles together!??

REGISTER NOW


No alt text provided for this image

Reuters Events: Pharma 2023 is the place where patient experts and pharma changemakers – from commercial, marketing, medical affairs, patient engagement, market access, RWE and Digital Health – share new best-practice, lessons learned and strategies for the future. #REpharma2023

Extended due to popular demand: Use code?VIPUPGRADE?on business passes purchased by March 10th. Save €500 and access annual learnings!

REGISTER NOW


That rounds off Issue 2 of the Pharma Digest.

We'll be back in two weeks with more important news, market updates, pharma content, and updates on our events. Don’t forget to subscribe to receive a notification for our next bi-weekly digest.

If you have ideas, suggestions, or questions for the team, don't hesitate to let us know in the comments, or get in touch directly.


USA Team

Kana Hutton – Marketing/ Commercial

Hannah Brady – Medical Affairs

Daisy Beale – Patient/ Cell and Gene

Charlotte Bastiaanse – RWE/ Market Access

?

EU Team

Daniel Baker – Marketing/ Commercial

Joey Buchholz – Medical Affairs

Usmaan Khan – Patient

Charlotte Bastiaanse – RWE/ Market Access

?

See you next time!

要查看或添加评论,请登录

Reuters Events Pharma的更多文章

社区洞察

其他会员也浏览了